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Abstract
There is growing interest in the use of structure-based virtual screening to identify small molecules 
that inhibit challenging protein–protein interactions (PPIs). In this study, we investigated how 
effectively chemical library members docked at the PPI interface mimic the position of critical 
side-chain residues known as “hot spots”. Three compound collections were considered, a 
commercially available screening collection (ChemDiv), a collection of diversity-oriented 
synthesis (DOS) compounds that contains natural-product-like small molecules, and a library 
constructed using established reactions (the “screenable chemical universe based on intuitive data 
organization”, SCUBIDOO). Three different tight PPIs for which hot-spot residues have been 
identified were selected for analysis: uPAR·uPA, TEAD4·Yap1, and CaVα·CaVβ. Analysis of 
library physicochemical properties was followed by docking to the PPI receptors. A 
pharmacophore method was used to measure overlap between small-molecule substituents and 
hot-spot side chains. Fragment-like conformationally restricted small molecules showed better hot-
spot overlap for interfaces with well-defined pockets such as uPAR·uPA, whereas better overlap 
was observed for more complex DOS compounds in interfaces lacking a well-defined binding site 
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such as TEAD4·Yap1. Virtual screening of conformationally restricted compounds targeting 
uPAR·uPA and TEAD4·Yap1 followed by experimental validation reinforce these findings, as the 
best hits were fragment-like and had few rotatable bonds for the former, while no hits were 
identified for the latter. Overall, such studies provide a framework for understanding PPIs in the 
context of additional chemical matter and new PPI definitions.
Graphical Abstract
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Introduction
Protein–protein interactions (PPIs) range in binding affinities from weak to tight.[1–3] PPIs 
have been classified into three categories: primary, secondary, and tertiary.[4] Primary 
interactions consist of a linear peptide segment bound to a protein receptor. A secondary 
interaction typically involves an α-helix or β-turn that is ensconced into a well-defined 
binding cavity. Tertiary interactions are more complex, usually containing multiple α -
helices and β-strands over large interfaces.[5] For primary interactions with druggable and 
relatively weak affinities (Kd > 0.1 μm), such as bromodomains, small-molecule inhibitors 
have been successfully developed; several compounds have advanced to clinical trials and 
one compound was FDA-approved.[6] Disruption of secondary and tertiary interactions with 
small molecules is more challenging. Small-molecule inhibitors of tight secondary and 
tertiary PPIs are relatively rare. Successful examples include inhibitors of MDM2·p53, but 
this interaction is weak (Kd ≈1 μm).[7] For tight interactions (Kd <100 nm), there are only a 
handful of small-molecule inhibitors for interactions such as Bcl-xL·Bak,[8] IL-2·IL-2Rα,[9] 
and more recently KEAP1·NRF2.[10]
There is growing interest in applying computational methods for the discovery of small-
molecule PPI inhibitors, particularly for tight secondary and tertiary interactions. We have 
successfully used virtual screening to identify inhibitors of the tight tertiary interaction 
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between the urokinase receptor uPAR and its protein ligand uPA with compounds ranging 
from sub-micromolar to micromolar affinity.[11–13] In one case, we screened multiple 
structures that were sampled from explicit-solvent molecular-dynamics simulations and 
identified a sub-micromolar affinity compound.[11] The predicted structure of the compound 
was independently confirmed by X-ray crystallography.[14] More recently, we introduced a 
fingerprint method that uses the native protein ligand as a guide to identify small molecules 
that mimic the interaction of the protein ligand.[13] Using the fingerprint method, we 
identified several hit compounds with single-digit micromolar affinities. Finding highly 
potent inhibitors of tight PPIs by virtual screening of commercial libraries remains 
extremely challenging, but we have shown that quality hit compounds with single-digit 
micromolar binding affinities can be identified.
Although progress has been made in the development of scoring and docking methods to 
enrich compound collections for the discovery of PPI inhibitor hit compounds, relatively 
little work has been done on the suitability of existing commercial and specialized 
collections for PPI drug discovery. Data-bases such as iPPI,[15] 2P2I,[16] and TIMBAL[17] 
have been created to explore additional chemotypes for PPIs. A few studies have explored 
whether commercial and specialized libraries contain small molecules that are suitable for 
disrupting PPIs.[18–20] These studies suggest that small-molecule PPI inhibitors tend to 
cover different chemical space than enzyme inhibitors. Another approach to determine 
whether a compound collection is enriched with compounds that are suitable for disrupting 
PPIs is to explore how effectively compounds mimic the side chains of critical amino acids 
of the PPI ligand protein, or whether compounds engage critical residues on the PPI receptor 
protein.[21] Small molecules that better mimic or engage critical residues are expected to be 
more effective inhibitors of PPIs.[22–24]
In this study, we explored how effectively small molecules in a commercial library 
(ChemDiv), a collection of diversity-oriented synthesis (DOS) libraries, and the “screenable 
chemical universe based on intuitive data organization” (SCUBIDOO) compound collections 
mimic the positions of critical residues at tight protein–protein interfaces. We employed a 
combined docking and pharmacophore approach to measure overlap between chemical 
structures and the side chains of interface residues. We selected three tight PPIs for which 
extensive alanine-scanning studies have identified critical hot-spot residues; these include 
the interaction between the urokinase receptor (uPAR) and its serine proteinase ligand 
urokinase (uPA), the transcription factor TEAD and its co-activator Yap (TEAD·Yap), and 
the α- and β-subunits of the voltage-gated calcium channels (CaVα·CaVβ). Our findings 
suggest that smaller conformationally restricted compounds show excellent overlap with hot 
spots. In a proof-of-concept study, we experimentally validated the compounds identified 
from virtual screening of a library of conformationally restricted commercially available 
compounds against the PPIs of uPAR·uPA and TEAD·Yap.
Results
Analysis of compound collection physicochemical properties
Several types of chemical libraries have been created over the years that may be suitable in 
identifying PPI inhibitors. Among them, diversity-oriented synthesis (DOS) represents a 
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strategy to efficiently generate compound collections with a high degree of structural 
diversity[25,26] and to produce new biological probes.[27–33] The DOS approach aims to 
achieve buildingblock, functional group, stereochemical, and skeletal diversity, occupying a 
middle ground between the structural complexity of natural products and the efficiency of 
commercially available synthetic libraries.[34] In addition to commercially available and 
DOS compounds, there is an increasing number of specialized libraries that have been 
constructed for use in virtual screening. These libraries were designed to overcome some of 
the shortcomings of commercial libraries, namely the limited chemical space commercial 
libraries cover and the large number of nuisance compounds.[35–37] The SCUBIDOO 
library[38] is one example. It consists of compounds constructed by combining building 
blocks from 58 organic reactions known to the pharmaceutical field.
To explore the structural overlap between small molecules and amino acid side chains at 
protein–protein interfaces, three compound collections from both commercial and non-
commercial sources were selected. The first was the commercially available library from 
ChemDiv, Inc. (ChemDiv), which is frequently used in compound screening. The second 
was a collection of DOS libraries[33,39] from the Broad Institute (DOS), and the third was 
SCUBIDOO.[38] The physicochemical properties of the compounds in each of the three 
collections were determined (Figure 1). Compounds in DOS had a mean molecular weight 
(MW) of 512±94 Da, which is larger than the mean molecular weight of compounds in 
ChemDiv (MW=410±74 Da) and SCUBIDOO (MW=327±49 Da) (Figure 1A). 
Lipophilicity, characterized here by computed AlogP values, plays a crucial role in 
determining solubility. Compounds in ChemDiv had a mean AlogP of 3.6±1.5 (Figure 1B). 
ChemDiv compounds are predicted to be generally less soluble than compounds from DOS 
or SCUBIDOO considering their substantially lower mean AlogP values of 2.3±1.6, and 
1.3±1.8, respectively.
To gain insight into the three-dimensional characteristics and complexity of compounds in 
these collections, the number of chiral centers was counted (Figure 1C). DOS compounds 
had generally more chiral centers (3.6±0.8), compared with SCUBIDOO (2.4±0.7) and 
ChemDiv compounds (0.7±1.2). These data confirmed that DOS compounds are generally 
more stereochemically complex than SCUBIDOO compounds. ChemDiv compounds 
showed a remarkably low number of chiral centers per compound compared with both DOS 
and SCUBIDOO.
A measure of flexibility is the number of rotatable bonds in a compound (Figure 1D). There 
were more rotatable bonds on average per compound in DOS (RB=6.8±2.1) compared with 
SCUBIDOO (RB=3.8±1.1) and ChemDiv (RB=5.5±2.1). The molecular weight of a 
compound was generally correlated with the number of rotatable bonds in the DOS 
(Pearson’s r= 0.68) and ChemDiv collections (r=0.55), but not in the SCUBIDOO library 
(r=0.13). There was a similar trend in the correlations between molecular weight and 
number of chiral centers in DOS (r=0.31), ChemDiv (r=0.20), and SCUBIDOO (r=0.08). 
Similarly, the number of chiral centers and rotatable bonds was only correlated in the DOS 
collection (r=0.27).
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Polar surface area (PSA) is a commonly used descriptor to provide insight into compound 
permeability and oral bioavailability.[40] In addition, PSA is often used in combination with 
the number of rotatable bonds to reflect molecular flexibility.[41] Compounds in DOS had 
the highest PSA values with a mean of 104±31 Å2, followed by ChemDiv (PSA=84±27 Å2) 
and SCUBIDOO (PSA=66±28 Å2) (Figure 1E). We found that PSA and the number of 
rotatable bonds were most strongly correlated in DOS (r=0.60) and ChemDiv (r=0.40), but 
not in SCUBIDOO (r=−0.02).
The number of hydrogen-bond donors (HBDs) and hydrogen-bond acceptors (HBAs) are 
important parameters related to compound polarity and membrane permeability. It has been 
suggested that the number of HBDs may be more important than the number of HBAs to 
enhance bioavailability and membrane permeability of lead compounds.[40,42,43] We found 
that DOS compounds had the highest number of HBDs and HBAs (HBD=2.0±0.9; 
HBA=5.2±1.6), followed by ChemDiv (HBD= 1.0±0.8; HBA=3.8±1.4) and SCUBIDOO 
(HBD=1.2±0.9; HBA=2.6±1.4) (Figure 1F,G). Among all the physicochemical properties 
that we have considered, only the ring count was similar among the three collections (Figure 
1H). Because SCUBIDOO was built by limiting the number of building blocks, compounds 
in SCUBIDOO have lower molecular weight and fewer rotatable bonds and chiral centers 
than compounds in DOS and ChemDiv.
We next compared the distributions of these eight physicochemical properties of the three 
collections using principal component analysis (PCA). Compounds from each of the three 
collections were projected onto the first two principal components (Figure 2A). In the first 
principal component, the distributions were separated such that there are distinct peaks for 
each of the three sources (PC1DOS =−1.6±1.7; PC1ChemDiv = 0.1±1.3; PC1SCUBIDOO 
=1.5±0.9). This effect is observed qualitatively in the marginal distributions for PC1 for each 
compound collection, where each set was projected onto different ranges of the first 
principal component. In the second principal component, however, the marginal distributions 
of DOS (PC2DOS = −0.5±0.9) and SCUBIDOO (PC2SCUBIDOO =−0.5±1.1) overlapped and 
each partially overlapped with the marginal distribution of ChemDiv (PC2ChemDiv 
=0.9±1.0). The loadings of the PCA are provided to illustrate the relative contributions of 
each of the eight input descriptors (Figure 2B). The total variance explained by the first two 
principal components were 44% and 18%, respectively. When the third principal component 
is included, the cumulative variance explained reached 76%.
To gain further insight into the structure of compounds in these three collections, the 
molecular shape diversity of each was evaluated using principal moments of inertia (PMI) 
(Figure 3). PMI plots represent the shape distribution of a collection of molecules. The three 
vertices of the triangular plot represent the extremes of molecular geometry. The top-left, 
top-right, and bottom corners correspond to small molecules with linear (e.g., diacetylene), 
spherical (e.g., adamantane), and disc-like (e.g., benzene) shapes, respectively. Compounds 
in SCUBIDOO (I1/I3 =0.26±0.12; I2/I3 =0.88±0.08) were predominantly linear relative to 
compounds in ChemDiv and DOS. ChemDiv (I1/I3 =0.31±0.13; I2/I3 =0.84±0.09) and DOS 
(I1/I3 = 0.33±0.12; I2/I3 =0.82±0.09) compounds were primarily along the diagonal between 
linear and disc-like structures. Despite the substantial difference in the number of chiral 
centers and rotatable between DOS (chiral center=3.6±0.8; RB=6.8±2.1) and ChemDiv 
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(chiral center=0.7±1.2; RB=5.5±2.1), there was little difference in the shape diversity 
between the two collections.
Compound overlap with protein–ligand hot spots at protein–protein interaction interfaces
We wondered if the chemical scaffolds found in each compound collection would yield 
compounds that could overlap and mimic the physicochemical properties of amino acid side 
chains at protein–protein interfaces. To explore this question, we selected three high-affinity 
(Kd <100 nm) PPIs with three distinct binding motifs: 1) a β-turn motif at the interface 
between the urokinase receptor and its serine proteinase ligand urokinase (uPAR·uPA); 2) a 
twisted-coil motif at the Ω-loop between the transcription factor TEAD and its co-activator 
Yap (TEAD·Yap); and 3) an a-helix motif between the α-and β-subunits of the calcium 
channel (CaVα·CaVβ).
We first docked compounds from the ChemDiv, DOS, and SCUBIDOO to the protein 
receptor at each of the three interaction interfaces. A ligand-based pharmacophore approach 
was used to identify compounds that overlap with interface residues on the protein ligand. 
Six possible pharmacophore features can be assigned to the side chains of protein residues: 
hydrogen-bond acceptor (A) and donor (D), hydrophobic group (H), negatively (N) and 
positively (P) charged group, and aromatic ring (R). These pharmacophore sites are 
characterized by type, location, and, if applicable, directionality.
uPAR·uPA—The uPAR·uPA interface consists primarily of a β-turn on the protein ligand 
uPA ensconced in a large pocket on the protein receptor uPAR, leading to an interaction that 
is both tight (Kd = 1 nm) and stable (koff =10−4 s−1) (Figure 4A,B). At the uPAR·uPA 
interface, the side chain of five hot-spot residues from uPA extend into the hydrophobic 
pocket of uPAR: Lys-23, Tyr-24, Phe-25, Ile-28, and Trp-30 (Figure 4C).[44] We used 
pharmacophores to represent the position and physicochemical properties of the side chains 
of these five residues. For a given pharmacophore, we compared each docked compound and 
determined whether it had a chemical moiety that overlaps with the pharmacophore with the 
appropriate physicochemical property. For example, a compound that possesses a benzene 
group that occupies the same position as an aromatic ring (pharmacophore) of a tyrosine 
residue on uPA is expected to mimic the properties of the tyrosine residue in the interaction 
between uPAR·uPA and disrupt binding. In the pharmacophore model, the ε-amine on 
Lys-23 was modeled using a positive charge feature, while the benzene rings of Tyr-24 and 
Phe-25 were modeled using aromatic ring features. We assigned separate aromatic ring 
features to the benzene and pyrrole rings on the indole of Trp-30. The aliphatic side chain of 
Ile-28 was represented by a hydrophobic feature centered at the Cα−Cγ1 bond. We searched 
for compounds containing functional moieties that matched a corresponding pharmacophore 
feature.
There were 31387, 3157, and 11 compounds in ChemDiv that overlap with one, two, and 
three distinct hot spots on uPA, respectively (Figure 4D). For DOS, fewer compounds were 
found to overlap with hot spots. In total, 19210, 952, and 10 compounds overlapped with 
one, two, and three hot spots, respectively (Figure 4E). The number of overlaps for 
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SCUBIDOO was similar to DOS, with 17992, 1033, and 8 compounds that overlapped with 
one, two, and three hot spots, respectively (Figure 4F).
There are differences in the degree of overlap with individual hot spots among the three 
collections. At Lys-23, DOS and SCUBIDOO compounds showed dramatically greater 
overlap compared with ChemDiv. A total of 1094 and 773 compounds from DOS and 
SCUBIDOO, respectively, overlapped with Lys-23 compared with only 72 for ChemDiv. 
Similarly, for compounds that overlapped with Lys-23 and one other hot spot, we found 161 
DOS and 184 SCUBIDOO compounds, compared with only 11 in ChemDiv. This finding 
might be attributed to the larger average AlogP value of ChemDiv (AlogP=3.6±1.6), which 
contains fewer polarizable moieties than DOS (AlogP=2.3±1.6) and SCUBIDOO 
(AlogP=1.3±1.8). Analogous trends were observed for both Ile-28 and Trp-30. At Ile-28, 
784 ChemDiv and 1674 DOS compounds overlapped with the residue, while only 70 
SCUBIDOO compounds showed overlap with this residue. At Trp-30, none of the 
compounds in ChemDiv or SCUBIDOO overlapped with either the indole or benzene rings 
of the side chain, while a total of 1772 compounds from DOS overlapped with Trp-30, 
including 213 compounds that overlap Trp-30 and at least one other residue. The latter 
finding may be attributed to the fact that Trp-30 is positioned outside of the deep binding 
pocket on uPAR, and may be more difficult to reach by the smaller compounds in ChemDiv 
and SCUBIDOO. When comparing the DOS compounds that overlap with Trp-30 to all 
DOS compounds, there was a slight shift in the distribution of aromatic rings from 4.0±0.9 
to 4.3±0.9, the distribution of rotatable bonds from 6.8±2.1 to 7.0±2.1, and the distribution 
of chiral centers from 3.6±0.8 to 3.7±0.7. Relative to DOS and SCUBIDOO, the number of 
compounds in ChemDiv that overlapped with Tyr-24 and Phe-25 was nearly double when 
considering only compounds that overlap with a single hotspot. Similarly, there was more 
than a threefold increase in the number of compounds that overlapped with Tyr-24 or Phe-25 
and one other hot spot. Although DOS compounds have proven successful in producing 
probe molecules after high-throughput screening, many of these compounds have high 
molecular weight.[39] Indeed, in our study, compounds from DOS that overlap with hot spots 
had higher molecular weight (MW=536:97 Da) than those from ChemDiv (MW=408±71 
Da) and SCUBIDOO (MW=332±45 Da).
A question of interest is whether compounds that are predicted by docking studies to have 
higher binding affinities will show different overlap with hot-spot residues at the protein–
protein interface. To address this question, we repeated the above analysis except that only 
compounds 1) that are 500 Da or less, and 2) that are among the top 1000 highest-scoring 
from a docking simulation were considered. There were 603, 433 and 605 compounds from 
ChemDiv, DOS, and SCUBIDOO that matched at least one hot spot (Figure 4D,E,F). 
ChemDiv and SCUBIDOO compounds all possessed substituents that occupy the same 
position as Lys-23, Tyr-24 or Phe-25 side chains on uPA, while none overlapped with hot 
spots on uPA located at Ile-28 and Trp-30. The DOS collection had only three compounds 
that overlapped these residues (Figure 4E). Furthermore, except for SCUBIDOO, none of 
the compounds in ChemDiv or DOS simultaneously showed an overlap with three hot spots. 
The four compounds from SCUBIDOO overlapped with Lys-23, Tyr-24, and Phe-25. It is 
interesting that compounds from SCUBIDOO, which are generally smaller in size than DOS 
and ChemDiv compounds, are able to mimic more hot spots at the protein–protein interface.
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TEAD·Yap—The PPI between TEAD and Yap occurs over a large interface of 1300 Å2.[45] 
The TEAD binding domain of Yap wraps around the globular structure of TEAD via three 
interfaces (Figure 5A). The twisted-coil region of Yap at the W-loop is most critical for 
complex formation (Figure 5B). There are six hot spots at this region, with four hydrophobic 
residues (Met-86, Leu-91, Phe-95, and Phe-96), one charged residue (Arg-89), and one polar 
residue (Ser-94). The aliphatic side chains of Met-86 and Leu-91 were identified as 
hydrophobic features in the pharmacophore model, the side chain of Arg-89 was modeled 
using a positive charge feature, and the benzene rings of Phe-95 and Phe-96 were modeled 
using aromatic ring features. The hydrogen and oxygen atom on the side chain of Ser-94 
were identified as a hydrogen-bond donor and acceptor, respectively (Figure 5C). In the 
native complex, two hydrogen bonds are formed between Ser-94 on Yap and Glu-240 and 
Tyr-406 on TEAD.[46]
There were 47061, 8862, 403, and 5 compounds in ChemDiv that overlapped with one, two, 
three, and four different hot spots on Yap, respectively (Figure 5D). From the DOS 
collection, 50976, 9570, 425, and 3 compounds overlapped with one, two, three, and four 
different hot spots on Yap, respectively (Figure 5E). From the SCUBIDOO library, only 
35369, 4341, and 59 compounds overlapped with one, two, and three hot spots 
simultaneously, while no compounds matched four hot spots (Figure 5F). Among 
compounds that overlapped with multiple hotspots, ChemDiv and DOS had similar 
distributions while SCUBIDOO had approximately half the number of compounds that 
overlapped with two hotspots and approximately 15% of the number of compounds that 
overlapped with three hotspots when compared with the other two collections.
In all three sets, approximately a quarter of all compounds overlapped with the hydrophobic 
pharmacophore on Met-86. Similarly, about 10% in each collection overlapped with the 
hydrophobic Leu-91 and aromatic Phe-95 residues on Yap. At Phe-96, DOS had 
substantially more compounds that overlapped with the residue either alone or with one 
other residue compared to the other two collections. Overlap with Arg-89, Ser-94, and 
Phe-95 were less prevalent in ChemDiv and SCUBIDOO compared to DOS. Moreover, no 
compounds in SCUBIDOO matched the pharmacophore of Ser-94. This observation may be 
attributed to the lower molecular weight and more limited structural diversity in this library, 
which limits the ability of compounds to overlap with residues that are outside the 
immediate binding pocket.
As with uPAR·uPA, we explored hot-spot overlap of compounds that were predicted by 
docking to have the highest binding affinities to the protein receptor, in this case TEAD4. A 
collection of compounds was created by selecting 1000 compounds with the highest binding 
scores and molecular weights less than 500 Da. In ChemDiv, there were 231 and 22 
compounds that overlapped with one or two hot spots, respectively (Figure 5D). In DOS, 
there were 390, 126, and 6 compounds that match one, two, and three hot spots, respectively 
(Figure 5E). From SCUBIDOO, we found a total of 354 and 39 compounds that matched the 
side chain of one or two hot spots, respectively (Figure 5F). The compounds in ChemDiv 
and SCUBIDOO mainly mapped onto the hydrophobic residues of Met-86, Leu-91, and 
Phe-95, while DOS compounds generally had overlap with Ser-94 and Met-86. Interestingly, 
no compound overlapped with Phe-96 from any of the three collections. Moreover, in DOS, 
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there were six compounds that with three hot spots simultaneously. All six compounds 
overlapped with Met-86 and have 6.8±1.9 rotatable bonds and 3.8±1.7 chiral centers. One 
compound overlapped with the nearby Arg-89, which is located at the periphery of the 
binding pocket. This compound is structurally complex (RB=7, chiral centers=3), but its 
molecular weight is only 345.3 Da, which suggests that compound flexibility may play a 
larger role than molecular weight in targeting the flat TEAD·Yap pocket.
CaVα·CaVβ—The structural basis of the CaVα·CaVβ interaction was revealed in a co-
crystal structure between CaVβ3 and the a-interacting domain (AID) of CaVα (CaVαAID) 
(Figure 6A). CaVαAID is a 25-residue α-helix that binds to a well-defined groove on the GK 
domain of CaVβ3 (Figure 6B). Previous biophysical studies combined with site-directed 
mutagenesis on CaVαAID revealed the presence of three hot-spot residues on the α-helix at 
Tyr-437, Trp-440, and Ile-441.[47] The side chains of these residues are ensconced into three 
sub-sites. The aliphatic side chain of Ile-441 was identified as a hydrophobic feature in the 
pharmacophore model, while the benzene ring of Tyr-437 was modeled using an aromatic 
ring feature. We assigned separate aromatic ring features to the benzene and pyrrole rings on 
the indole of Trp-440 (Figure 6C).
There were 59171, 38940, and 2099 compounds in ChemDiv that overlapped with one, two, 
and three hot spots, respectively (Figure 6D). From DOS and SCUBIDOO, substantially 
fewer compounds were found to overlap with multiple hot spots. There were 58219, 13350, 
and 476 compounds from DOS that overlapped with one, two, and three separate hot spots, 
respectively (Figure 6E), and correspondingly 45097, 15757, and 40 from SCUBIDOO 
(Figure 6F). While the number of compounds that overlap with a single hot spot are similar, 
the number of compounds that overlap with two or three hot spots is substantially different 
for ChemDiv compared to DOS and SCUBIDOO. The largest difference was seen in 
compounds that overlap with either Tyr-437 or Trp-440 as well as one other hot spot. In 
ChemDiv, approximately 35000 compounds overlapped with one of the two aromatic hot 
spots as well as another residue. If a compound in ChemDiv was overlapping with multiple 
residues, it was often at both the Tyr-437 and Trp-440 sites, while fewer compounds 
overlapped with one of these two aromatic residues and the hydrophobic Ile-441. This trend 
was also observed in SCUBIDOO, where there was much higher co-occurrence of a 
combination of Tyr-437 and Trp-440 than between one of the two aromatic residues and 
Ile-441. Among DOS compounds, in contrast, the co-occurrence rate between the three 
residues was more uniform, with 7980, 9767, and 8953 compounds that overlapped with 
Tyr-437, Trp-40, and Ile-441 and one other residue, respectively.
We again considered compounds with highest predicted binding affinities and low molecular 
weight. The top highest-scoring 1000 compounds with molecular weights less than 500 Da 
were selected based on docking score (Figure 6D–F). There were 936, 812, and 951 
compounds for ChemDiv, DOS, and SCUBIDOO matching at least one hot spot. It is 
interesting that despite the higher complexity of DOS compounds (chiral centers=3.5±1.0) 
fewer matched hot spots than ChemDiv and SCUBIDOO compounds, which are less rich in 
chiral centers (ChemDiv chiral centers=0.4±0.7; SCUBIDOO chiral centers=1.3±1.0). 
Interestingly, there were twice as many compounds in ChemDiv and SCUBIDOO that 
overlapped with at least two hot spots than DOS. Remarkably, there were 50 compounds in 
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ChemDiv that overlapped with three hot spots relative to only two each for DOS and 
SCUBIDOO.
Virtual screening of commercial library against two protein–protein interactions
The discovery that conformationally restricted fragment-like libraries such as SCUBIDOO 
can be effective in mimicking protein–ligand hot spots for interfaces with well-defined 
pockets prompted us to test this observation with virtual screening and experimental 
validation. The ChemDiv commercial library was filtered for conformationally restricted 
compounds and tested against the uPAR·uPA interaction. The ChemDiv library was filtered 
for compounds between 350 and 500 Da having six or fewer rotatable bonds as well as high 
predicted solubility (AlogP ≤ 4). The resulting collection of 50,893 compounds was docked 
to uPAR at the uPAR·uPA interface and to TEAD at the TEAD·Yap interface. Compounds 
were ranked based on their overlap with hot spots located at the protein–protein interface. 
The top 85 compounds were selected and tested for inhibition of uPAR·uPA and TEAD·Yap 
using a previously developed fluorescence polarization assay. The compounds were first 
tested in duplicate at a single concentration of 50 μm (Figure 7A). For the uPAR·uPA 
interface, five compounds, namely 1 (IPR-3247), 2 (IPR-3260), 3 (IPR-3271), 4 (IPR-3288) 
and 5 (IPR-3305) inhibited more than 25% (Supporting Information Table S1). These 
compounds were also tested in a concentration-dependent manner (Figure 7B). All five 
compounds inhibited the FP assay, with Ki values in the double-digit micromolar range. All 
five were predicted to overlap with two aromatic hot spots on uPA, Tyr-24 and Phe-25 
(Figure 7C). Compound 2, however, ap-pears to have poor solubility at concentrations that 
are higher than 25 μm. Compounds 3 and 5 also exhibited poor solubility at higher 
concentrations. The two compounds with reasonably good solubility were 1 and 4 with Ki 
values of 25 and 62 μm, respectively.
Conformationally restricted compounds from ChemDiv were docked against TEAD at the 
TEAD4·Yap interface. The top 81 compounds from virtual screening against the Ω-loop 
pocket on TEAD4 were experimentally validated using a fluorescence polarization assay. 
Compounds were tested in duplicate at an initial concentration of 50 μm (Figure 7D). No 
compounds were found to inhibit more than 15%. TED-97, a previously discovered small-
molecule inhibitor of TEAD4·Yap1 was used as positive control. A concentration-dependent 
study was performed for compounds that inhibited by 15%, but none exhibited 
concentration-dependent inhibition. The lack of hits confirms the highly challenging nature 
of this interaction and the fact that to successfully inhibit this target, larger more complex 
compounds such as DOS may be required. It is interesting to note that compounds in 
ChemDiv are generally different from the more complex DOS library compounds (see 
Figure 1). Furthermore, the overlap of ChemDiv compounds and DOS compounds with hot 
spots at the TEAD·Yap interface is different for both the whole library than for the top 1000 
compounds (see Figure 5).
The ranking of the filtered and unfiltered compound sets from uPAR was compared to 
determine whether pre-filtering by rotatable bonds, molecular weight, and AlogP led to 
further enrichment of the original library for hit compounds. We identified the ranking of the 
five active compounds using the distribution of docking scores of the compounds in the 
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unfiltered ChemDiv library (Supporting Information Figure S1). For the unfiltered library, 
we found that four of the five hit compounds have docking scores that puts them between the 
25th and 75th percentiles. In other words, had we strictly ranked the unfiltered library, these 
hit compounds would not have been selected as they would not have been among the top 
candidates chosen for experimental validation. Only compound 3 (IPR3271) would have 
been among the top 100 compounds in the unfiltered library (i.e., without physicochemical 
filters).
Discussion
Three chemical libraries were compared for their ability to mimic the positions of amino 
acid side chains of critical residues at protein–protein interfaces: 1) a commercial library 
from ChemDiv; 2) a collection of diversity-oriented synthesis (DOS) libraries from the 
Broad Institute; and 3) SCUBIDOO, a non-commercial library built by combining building 
blocks of common reactions in medicinal chemistry. The physicochemical properties of each 
of these three collections was explored. DOS compounds were larger, had more chiral 
centers, and were more flexible as evidenced by a larger number of rotatable bonds 
compared with ChemDiv and SCUBIDOO. Similarly, the molecular weight distributions of 
the compound collections correlates well with the number of rotatable bonds and chiral 
centers in DOS and ChemDiv, but not SCUBIDOO. Principal component analysis revealed a 
primary separation of all three collections in the first component, while the second principal 
component did not distinguish DOS from SCUBIDOO libraries. Finally, principal moment 
of inertia analysis suggests that compounds in the SCUBIDOO library are enriched for 
linear compounds, while ChemDiv and DOS contain compounds with more disc-like and 
some globular characteristics.
We explored the ability of these three compound collections to mimic the physicochemical 
properties of amino acid side chains of hot spots at the interface of three PPIs. Three tight 
PPIs were selected: 1) a β-turn motif at the interface between the urokinase receptor and its 
serine proteinase ligand urokinase (uPAR·uPA), 2) a twisted-coil motif at the Ω-loop 
between the transcription factor TEAD and its co-activator Yap (TEAD·Yap), and 3) an a-
helix motif between the α-and β-subunits of the calcium channel (CaVα·CaVβ). In each 
system, hot-spot residues were identified on the protein ligand at each PPI interface. Each 
library showed different overlap with individual hot spots in each PPI. For example, for 
uPAR·uPA, ChemDiv contains more compounds that overlap with the two aromatic residues 
Tyr-24 and Phe-25, while DOS and SCUBIDOO possess many more compounds that 
overlap with the positively charged Lys-23 residue. Similarly, DOS was twice as likely to 
overlap with Ile-28 than ChemDiv and 20 times as likely than SCUBIDOO. DOS was also 
the only collection to have compounds that overlapped with the more distant Trp-30 hot 
spot. Similar trends were observed in TEAD·Yap, where DOS compounds were better able 
to mimic Arg-89, Ser-94, and Phe-96 than those of ChemDiv and SCUBIDOO, but 
ChemDiv compounds were better able to mimic Phe-95 than the other two collections. In 
CaVα·CaVβ, we found similar distributions in the number of compounds that overlapped 
with a single hot spot, but more than two and four times the number of compounds that 
overlapped with two and three distinct hot spots in ChemDiv compared to DOS. The gap is 
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further exacerbated when comparing ChemDiv and SCUBIDOO, where there were two and 
50 times as many compounds that overlapped with two and three hot spots, respectively.
We refined our analysis, except that the top 1000 best scoring compounds by docking 
simulation were selected, subject to a molecular weight filter. This new set of compounds 
was enriched for small molecules predicted to bind to the target with high affinity. 
Interestingly, there were many more small molecules from ChemDiv and SCUBIDOO that 
overlapped with at least two hot spots for uPAR·uPA and CaVα·CaVβ. In fact, for the 
CaVα·CaVβ interaction, there were more than 50 compounds in ChemDiv that overlapped 
with three hot spots, compared with only two for both DOS and SCUBIDOO. For 
TEAD4·Yap1, the DOS collection showed substantially greater overlap. These results can be 
explained by the fact that when compounds are ranked by their binding affinity, the resulting 
set is likely enriched for small molecules that make the best shape complementarity with 
existing pockets and therefore result in the largest solvent-accessible surface area change. In 
the case of uPAR and CaV0β, both receptors possess well-defined binding pockets. 
Considering that ChemDiv and SCUBIDOO possess a large number of small fragment-like 
compounds, it is more likely that these compounds will fit best into pockets and sub-pockets 
of these receptors. DOS compounds, on the other hand, are larger and more flexible, and 
may not score as well as SCUBIDOO and ChemDiv library small molecules, which may 
explain why there are fewer of these compounds that overlap with two or more hot spots in 
the top 1000 set. Because TEAD4 has a shallow pocket, DOS compounds will probably 
score higher, as for a flat surface, a larger compound is much more likely to lead to greater 
surface burial and therefore a better score. These results were tested by carrying out a virtual 
screen of more than 50000 compounds from the ChemDiv library against uPAR and TEAD. 
We selected conformationally restricted compounds between 350 and 500 Da in MW. 
Interestingly, several hits emerged in uPAR, and the most promising among them are 
fragment-like hits that have 2–3 rotatable bonds. No hits were identified for TEAD4.
Our work suggests that small fragment-like compounds that are conformationally restricted 
can be good candidates for PPI with well-defined pockets, while larger more complex 
compounds may be a better option for PPI with large but flat and featureless surfaces. The 
affinity of large hit compounds is generally driven by entropy, so these compounds may not 
show optimal fit to smaller, well-defined binding pockets. Hence, improving the enthalpy of 
binding becomes a significant challenge that is only accomplished by substantial 
modifications to the compound structure. Small fragment-like compounds are generally 
driven by enthalpy. These compounds tend to show optimal fit into pockets. It is easier to 
modify these compounds by extending them into neighboring pockets while at the same time 
improving entropy of binding.
Experimental Section
Ligand preparation:
Three libraries were chosen to compare how compounds mimicked the hot-spot residues on 
the different PPI interfaces. The first is the ChemDiv library, which consists of over 1.7 
million compounds that were retrieved from the ZINC15 website.[48] The second collection 
is a set of diversity-oriented synthesis (DOS) libraries prepared at the Broad Institute 
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(Supporting Information Table S2). This collection consists of 100903 compounds from 32 
libraries that were synthesized using DOS principles applied to 11 different reaction 
pathways.[33,39] The third collection is from SCUBIDOO, which was developed from 58 
organic reactions known in the pharmaceutical field totaling over 21 million compounds.[38] 
The SCUBIDOO website provides three different representative samples created using a 
stratified sampling algorithm. We selected the M library from SCUBIDOO consisting of 
99977 compounds. Compounds predicted to be pan-assay interference compounds (PAINS) 
were identified and filtered using the PAINS1, PAINS2, and PAINS3 filters in Canvas,[49,50] 
resulting in 1428800 compounds for ChemDiv, 99663 compounds for DOS, and 93074 
compounds for SCUBIDOO. ChemDiv compounds retrieved from ZINC were previously 
prepared through their internal workflow.[51] Compounds from DOS and SCUBIDOO were 
prepared using LigPrep.[52] Epik was used for protonation-state assignment and tautomer 
generation.[53] The OPLS_2005 force field was used for minimization and the ionization 
sates were generated at pH 7.[54] Compounds were desalted to exclude additional molecules 
such as counter ions in salt and water molecules and tautomers were generated. For DOS 
and SCUBIDOO, stereoisomers were generated by retaining specified chiralities and varying 
those where the stereochemistry of the chiral center were undefined. Up to 32 different 
stereoisomers per ligand were generated in this manner, resulting in 127483 compounds for 
DOS and 125917 compounds for SCUBIDOO. The size of each compound library was 
normalized by random sampling to 125917 compounds.
Principal component analysis:
Principal component analysis (PCA) aims to simplify high-dimensional data by projecting 
the data onto a new set of dimensions that most effectively captures the variance in the data. 
We used it to visualize similarities and differences between the physicochemical properties 
of different collections of compounds. Eight physicochemical features were used for PCA: 
molecular weight (MW), AlogP, number of hydrogen-bond acceptors (HBA), number of 
hydrogen-bond donors (HBD), number of rotatable bonds (RB), polar surface area (PSA), 
number of chiral centers, and number of rings. The mean of each feature is shifted to zero 
and each feature is scaled to have unit variance prior to the analysis. PCA is calculated using 
singular value decomposition in R (version3.2.3).
Principal moment of inertia:
Principal moment of inertia (PMI) descriptors provide an intuitive notion of the three-
dimensional shape diversity of the various compound data sets. Lowenergy conformations 
are identified for each molecule in the data set, and three PMI values (I1, I2 and I3; where I3 
≥I2 ≥I1) are calculated for each conformer. Normalized ratios of PMI (I1/ I3 and I2/ I3) are 
then calculated and plotted on a triangular graph, with the vertices (0,1), (0.5,0.5), and (1,1) 
representing a perfect linear (diacetylene), disc-like (benzene), and spherical (adamantane) 
compound, respectively. The moments of inertia in the three spatial dimensions were 
calculated by the calculate_pmi.py script in Schrödinger.
Protein preparation:
The structures of the uPAR·uPA (PDB ID: 3BT1), TEAD·Yap (PDB ID: 3KYS), and 
CaVα·CaVβ (PDB ID: 1VYT) interactions were retrieved and prepared using the Protein 
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Preparation Wizard using the Schrçdinger Suite.[52,55] Bond orders were assigned, hydrogen 
atoms were added, and disulfide bonds were created. Water residues and additional ions and 
heteroatom groups were discarded. Missing side chains and loops were introduced using the 
Prime module.[56] The resulting protein structures were protonated at pH 7.0 using 
PROPKA.[57]
Virtual screening:
The compound library was docked to the prepared protein structures using AutoDock Vina 
(Version 1.1.2).[58] The binding pocket was centered at each of the interfaces with a box 
with dimensions of 21 Å×21 Å×21 Å. All other parameters were set to default values. The 
docked conformations were converted back to MOL2 format using inhouse Python scripts 
for additional analysis. Glide was used to score the Vina-docked binding modes in place 
using the GlideHTVS scoring function.[59,60]
Ligand pharmacophore:
A previously described[13] pharmacophore-based approach was adapted and used to identify 
how docking compounds overlapped with and mimicked known hot spots of the protein 
ligand in each of the protein–protein complexes. A set of pharmacophore hypotheses was 
constructed corresponding to the physicochemical properties of the protein ligand side chain 
using the Phase package in Schrödinger.[61,62] Phase has six built-in types of pharmacophore 
features: 1) hydrogen-bond acceptor (A); 2) hydrogen-bond donor (D); 3) hydrophobe (H); 
4) negative ionizable (N); 5) positive ionizable (P); and 6) aromatic ring (R). The docked 
ligand conformation was used for pharmacophore calculations with an inter-site distance 
matching tolerance of 2.0 Å. Hydrogen-bond acceptor sites were positioned on atoms that 
carry one or more donatable lone pairs, while hydrogen-bond donor sites were centered on 
each electrophilic site. Negative and positive ionizable sites were modeled as single points 
located on a formally charged atom, or at the centroid of a group of atoms over which the 
ionic charge is shared. Rings, isopropyl groups, tert-butyl groups, various halogenated 
moieties, and aliphatic chains are treated as hydrophobic sites.[61] Aromatic rings were 
distinguished from other hydrophobic groups and designated as a separate type of 
pharmacophore feature (i.e., “R” rather than “H”). In these cases, a single site was placed at 
the centroid of each aromatic ring. In aromatic ring pharmacophores, a normal vector was 
projected orthogonal to the plane of each ring. Similarly, in positive and negative ionizable 
pharmacophores (i.e., “P” and “N”, respectively), a vector parallel to the plane of the 
respective atom was formed.
Compound conformers from virtual screening were used to identify matches without 
refinement using Phase’s default fitness function. In this scoring function, three factors are 
used to describe the degree to which a compound matches a pharmacophore feature: 1) the 
site score, which describes how well the compound superimposes the pharmacophore 
feature, 2) the vector score, which describes the cosine angle between the normal vector of 
an aromatic ring on the compound with an aromatic feature, and 3) the volume score, which 
describes the proportion of the total volume of the pharmacophore feature overlapped by the 
compound. The vector score ranges from −1.0 (antiparallel) to 1.0 (parallel) in positive and 
negative ionizable pharmacophores, and 0.0 (perpendicular) to 1.0 (parallel) in aromatic 
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pharmacophores. Vector scores less than 0.8, corresponding to angles more than ±37°, were 
rejected. Compounds with either root-mean-square deviation (RMSD) overlap greater than 
1.2 Å or that did not overlap with the pharmacophore feature were discarded. All other 
parameters were set at default values. The remaining compounds that matched a given 
pharmacophore were retained without sorting compounds by Phase’s internal scoring 
function.
Fluorescence polarization (FP) assay:
Polarized fluorescence intensities were measured using EnVision Multilabel plate readers 
(PerkinElmer, Waltham, MA, USA) with excitation and emission wavelengths of 485 and 
535 nm, respectively.[11] Samples were prepared in Thermo Scientific Nunc 384-well black 
microplate in duplicates. First, the compounds were diluted in DMSO and further diluted in 
1× PBS buffer with 0.01% Triton X-100 for a final concentration of 200–0.2 3μm. Triton 
X-100 was added to the buffer to avoid compound aggregation. 5 mL of the compound 
solution and 40 μL of PBS with 0.01% Triton X-100 containing uPAR was added to the 
wells and incubated for at least 15 min to allow the compound to bind to the protein. Finally, 
5 μL of fluorescent AE147-FAM peptide solution was added for a total volume of 50 μL in 
each well resulting in final uPAR and peptide concentrations of 250 nm and 100 nm 
respectively. For the TEAD4·Yap1 FP assay, final concentrations of 64 nm GST-TEAD4 
(217–434) and 16 nm FAM-labeled Yap1 peptide (residues 60–99) were used. The final 
DMSO concentration was 2% v/v, which had no effect on the binding of the peptide. 
Controls included wells containing only the peptide, and wells containing both protein and 
peptide, each in duplicate to ensure the reproducibility of the assay. When compounds were 
insoluble and visible precipitation was observed, the data points at high concentrations were 
not included in the calculation of IC50 values. Inhibition constants were calculated from the 
IC50 values using the Ki calculator available at http://sw16.im.med.umich.edu/software/
calc_ki/.
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Figure 1. 
Distributions of individual physicochemical properties of the ChemDiv, DOS, and 
SCUBIDOO compound collections highlight differences in size, flexibility, and complexity.
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Figure 2. 
Principal component analysis (PCA) of physicochemical property space for ChemDiv (red), 
DOS (green), and SCUBIDOO (blue) illustrates similarities and differences between these 
collections. A) Compounds from each of the three collections were projected onto the first 
two principal components, each of which is also represented by its marginal distribution on a 
per-collection basis. B) Loading levels for the first three principal components (>75% 
cumulative variance) on the input features.
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Figure 3. 
Principal moments of inertia (PMI) illustrate the shape diversity of three compound 
collections. The top left-hand corner represents a linear molecule (e.g., diacetylene), the top 
right-hand corner represents a spherical molecule (e.g., adamantane) and the bottom corner 
represents a disc-like molecule (e.g., benzene).
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Figure 4. 
The protein complex of uPAR and uPA peptide. A) uPAR is shown as a surface colored by 
hydrophobicity, with more hydrophobic residues in brown and more hydrophilic residues in 
green. The uPA peptide is shown as a cyan ribbon. B) The uPAR·uPA complex and the five 
hot spots (side chains in stick representation) on uPA (cyan ribbon). C) Pharmacophore 
features for uPA are shown as small colored spheres: positive charge (Lys-23 in dark blue), 
hydrophobic (Ile-28 in green), and aromatic rings (Tyr-24, Phe-25, Trp-30 in tan). D) The 
matching count for compounds in ChemDiv that overlap with one, two, or three distinct hot 
spots on uPA using the whole collection and the top 1000 compounds (highest docking 
scores with MW ≤ 500 Da), respectively. E) The matching count for compounds in DOS that 
overlap with one, two, or three distinct hot spots on uPA using the whole collection and the 
top 1000 compounds, respectively. F) The matching count for compounds in SCUBIDOO 
that overlap with one, two, or three distinct hot spots on uPA using the whole library and the 
top 1000 compounds, respectively.
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Figure 5. 
The protein complex of TEAD and YAP peptide. A) TEAD is shown as a surface colored by 
hydrophobicity, with more hydrophobic residues in brown and more hydrophilic residues in 
green. The YAP peptide is shown as a cyan ribbon. B) The TEAD·YAP complex and the six 
hot spots (side chains in stick representation) on YAP (cyan ribbon). C) Pharmacophore 
features for YAP are shown as small colored spheres: hydrophobic (Met-86 and Leu-91 in 
green), positive charge (Arg-89 in dark blue), hydrogen-bond acceptor (Ser-94 in red), 
hydrogen-bond donor (Ser-94 in light blue), and aromatic rings (Phe-95, Phe-96 in tan). D) 
The matching count for compounds in ChemDiv that overlap with one, two, or three distinct 
hot spots on YAP using the whole collection and the top 1000 compounds (highest docking 
scores with MW ≤ 500 Da), respectively. E) The matching count for compounds in DOS that 
overlap with one, two, or three distinct hot spots on YAP using the whole collection and the 
top 1000 compounds, respectively. F) The matching count for compounds in SCUBIDOO 
that overlap with one, two, or three distinct hot spots on YAP using the whole library and the 
top 1000 compounds, respectively.
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Figure 6. 
The protein complex of CaVβ and CaVα peptide. A) CaVβ3 is shown as a surface colored by 
hydrophobicity, with more hydrophobic residues in brown and more hydrophilic residues in 
green. The CaVα peptide is shown as a cyan ribbon. B) The CaVα·CaVβ3 complex and the 
three hot spots (side chains in stick representation) on CaVα (cyan ribbon). C) 
Pharmacophore features for CaVα are shown as small colored spheres: hydrophobic (Ile-441 
in green) and aromatic rings (Tyr-437, Trp-440 in tan). D) The matching count for 
compounds in ChemDiv that overlap with one, two, or three distinct hot spots on CaVα 
using the whole collection and the top 1000 compounds (highest docking scores with MW ≤ 
500 Da), respectively. E) The matching count for compounds in DOS that overlap with one, 
two, or three distinct hot spots on CaVα using the whole collection and the top 1000 
compounds, respectively. F) The matching count for compounds in SCUBIDOO that overlap 
with one, two, or three distinct hot spots on CaVα using the whole library and the top 1000 
compounds, respectively.
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Figure 7. 
A) A set of 85 compounds from virtual screening were tested at a single concentration of 50 
μM in a fluorescence polarization (FP) assay for inhibition of uPAR·AE147 interaction. 
Structures are provided for compounds 1–5 (green bars) that were advanced to 
concentration-response experiments. B) Concentration-dependent FP assay measuring the 
inhibition of uPAR·AE147-FAM peptide interaction by compounds. At high concentrations, 
some compounds were insoluble and high-concentration data points were omitted from 
curve-fitting. C) Virtual screening binding modes of 1–5 (yellow sticks) in the uPAR·uPA 
binding pocket. uPAR is shown as a white surface and ribbons on the left and right, 
respectively. uPA is shown as a partially transparent cyan ribbon. The side chains of four 
interface residues on uPA are shown as a stick representation and colored cyan. D) A set of 
81 compounds from virtual screening were tested at a single concentration of 50 μm for 
inhibition of a FP-based GST-TEAD4·Yap interaction assay. Compounds were selected to 
target the W-loop pocket on TEAD4 and were limited to be conformationally restrictive (i.e., 
350 ≤ MW ≤ 500, RB ≤ 6, AlogP ≤ 4).
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